We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+16.08%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$232M
AUM Growth
-$281M
Cap. Flow
-$304M
Cap. Flow %
-130.94%
Top 10 Hldgs %
35.11%
Holding
133
New
10
Increased
39
Reduced
47
Closed
29

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$4.1M
2
SLRN
ACELYRIN
SLRN
+$2.78M
3
MRK icon
Merck
MRK
+$2.54M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$2.3M
5
TVTX icon
Travere Therapeutics
TVTX
+$2M

Top Sells

Rank Stock Value
1
RCM
R1 RCM Inc. Common Stock
RCM
+$11.2M
2
BPMC
Blueprint Medicines
BPMC
+$10.6M
3
HQY icon
HealthEquity
HQY
+$10.5M
4
EVH icon
Evolent Health
EVH
+$10.4M
5
RDNT icon
RadNet
RDNT
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.21%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
51
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$1.82M 0.79%
20,439
-4,236
-17% -$315K
MLTX icon
52
MoonLake Immunotherapeutics
MLTX
$1.57B
$1.81M 0.78%
30,005
-67,960
-69% -$3.5M
AZN icon
53
AstraZeneca
AZN
$263B
$1.76M 0.76%
13,065
+655
+5% +$85.1K
BCAB icon
54
BioAtla
BCAB
$5.46M
$1.74M 0.75%
14,121
– –
PRTA icon
55
Prothena Corp
PRTA
$425M
$1.7M 0.73%
46,777
-125,630
-73% -$4.84M
EW icon
56
Edwards Lifesciences
EW
$49.6B
$1.67M 0.72%
21,900
-27,300
-55% -$1.9M
VSTM icon
57
Verastem
VSTM
$510M
$1.66M 0.71%
203,327
– –
IOVA icon
58
Iovance Biotherapeutics
IOVA
$1.82B
$1.62M 0.7%
198,800
-786,200
-80% -$4.11M
MRNA icon
59
Moderna
MRNA
$21.8B
$1.6M 0.69%
16,100
+1,100
+7% +$92.5K
TSBX
60
DELISTED
Turnstone Biologics
TSBX
$1.32M 0.57%
517,648
– –
AMLX icon
61
Amylyx Pharmaceuticals
AMLX
$2.26B
$1.24M 0.53%
84,055
+10,400
+14% +$159K
LENZ
62
LENZ Therapeutics
LENZ
$166M
$1.16M 0.5%
+63,118
New +$1.04M
EFTR
63
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$1.11M 0.48%
95,306
– –
ILMN icon
64
Illumina
ILMN
$31B
$919K 0.4%
6,785
+309
+5% +$35.6K
KRTX
65
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$707K 0.3%
2,235
-23,745
-91% -$4.62M
SNY icon
66
Sanofi
SNY
$103B
$701K 0.3%
14,090
+1,260
+10% +$61.6K
ONC
67
BeOne Medicines Ltd
ONC
$32.8B
$677K 0.29%
3,752
+420
+13% +$76K
INCY icon
68
Incyte
INCY
$24.2B
$634K 0.27%
10,105
+460
+5% +$26K
UTHR icon
69
United Therapeutics
UTHR
$25.8B
$619K 0.27%
2,815
+200
+8% +$46.1K
NBIX icon
70
Neurocrine Biosciences
NBIX
$16.8B
$586K 0.25%
4,445
+410
+10% +$47.2K
CYTK icon
71
Cytokinetics
CYTK
$10.5B
$586K 0.25%
7,013
-111,290
-94% -$4.03M
RPRX icon
72
Royalty Pharma
RPRX
$25.9B
$578K 0.25%
20,570
+2,620
+15% +$72K
ASND icon
73
Ascendis Pharma A/S
ASND
$16B
$559K 0.24%
4,441
+200
+5% +$19.9K
FUSN
74
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$551K 0.24%
57,297
– –
ITCI
75
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$531K 0.23%
7,420
-116,260
-94% -$6.69M
1 2
3
4 5

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
AAA
AG Asset Advisory Los Angeles, California $121M AUM 10.78% 1-Year Est. Return
TGM
Tenzing Global Management San Francisco, California $121M AUM 85.62% 1-Year Est. Return

Sectoral Asset Management's Q4 2023 Portfolio in Review

As of Q4 2023, Sectoral Asset Management held 133 positions worth $232M, down 55% from $514M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Sectoral Asset Management withdrew a net $304M in Q4 2023, closing 29 positions and reducing 47 holdings. Its most notable exit was R1 RCM Inc. Common Stock, an estimated $11.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Industrials.

Against the trend, Sectoral Asset Management opened a new position in ACELYRIN worth $2.43M.

  • Sectoral Asset Management's largest Q4 2023 buy was ACELYRIN: 325,549 shares worth $2.43M.
  • Sectoral Asset Management added most to argenx in Q4 2023, an estimated $4.1M increase.
  • Sectoral Asset Management's biggest Q4 2023 reduction was Blueprint Medicines, cutting an estimated $10.6M.
  • Sectoral Asset Management fully exited R1 RCM Inc. Common Stock in Q4 2023, selling an estimated $11.2M.
  • Sectoral Asset Management's ten largest holdings make up 35% of its $232M portfolio in Q4 2023.
  • Sectoral Asset Management opened 10 new positions and closed 29 in Q4 2023.
  • Sectoral Asset Management's portfolio value fell 55% quarter-over-quarter to $232M.

Based on Sectoral Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.